Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 4698167, 8 pages
https://doi.org/10.1155/2017/4698167
Research Article

TXNRD1 Is an Unfavorable Prognostic Factor for Patients with Hepatocellular Carcinoma

1Department of Hepatic Surgery and Liver Transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute of Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, Guangzhou 510630, China
2Department of General Surgery, The Second People’s Hospital of Guangdong Province, Guangzhou 510317, China
3Guangdong Provincial Key Laboratory of Liver Disease Research and Key Laboratory of Clinical & Translational Research on Biotherapy for Liver Disease of Guangdong Higher Education Institutes and Cell-Gene Therapy Translational Medicine Research Center of The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510630, China

Correspondence should be addressed to Wei Liu and Tong Zhang

Received 5 December 2016; Revised 6 February 2017; Accepted 12 February 2017; Published 27 April 2017

Academic Editor: Noriyoshi Sawabata

Copyright © 2017 Binsheng Fu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Nguyen, R. T. Awwad, D. D. K. Smart, D. R. Spitz, and D. Gius, “Thioredoxin reductase as a novel molecular target for cancer therapy,” Cancer Letters, vol. 236, no. 2, pp. 164–174, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. E. S. J. Arnér and A. Holmgren, “Physiological functions of thioredoxin and thioredoxin reductase,” European Journal of Biochemistry, vol. 267, no. 20, pp. 6102–6109, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Iwasawa, Y. Yamano, Y. Takiguchi, H. Tanzawa, K. Tatsumi, and K. Uzawa, “Upregulation of thioredoxin reductase 1 in human oral squamous cell carcinoma,” Oncology Reports, vol. 25, no. 3, pp. 637–644, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. P. Fernandes, A. Capitanio, M. Selenius, O. Brodin, A.-K. Rundlöf, and M. Björnstedt, “Expression profiles of thioredoxin family proteins in human lung cancer tissue: correlation with proliferation and differentiation,” Histopathology, vol. 55, no. 3, pp. 313–320, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Soini, K. Kahlos, U. Näpänkangas et al., “Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma,” Clinical Cancer Research, vol. 7, no. 6, pp. 1750–1757, 2001. View at Google Scholar · View at Scopus
  7. A. Cañas, L. M. López-Sánchez, A. Valverde-Estepa et al., “Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors,” Breast Cancer Research, vol. 14, no. 6, article R153, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Cadenas, D. Franckenstein, M. Schmidt et al., “Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer,” Breast Cancer Research, vol. 12, no. 3, article R44, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Esen, F. Erdi, B. Kaya, B. Feyzioglu, F. Keskin, and L. S. Demir, “Tissue thioredoxin reductase-1 expression in astrocytomas of different grades,” Journal of Neuro-Oncology, vol. 121, no. 3, pp. 451–458, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. B. A. Carlson, M.-H. Yoo, R. Tobe et al., “Thioredoxin reductase 1 protects against chemically induced hepatocarcinogenesis via control of cellular redox homeostasis,” Carcinogenesis, vol. 33, no. 9, pp. 1806–1813, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Duan, B. Zhang, J. Yao et al., “Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase,” Free Radical Biology and Medicine, vol. 69, pp. 15–25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Chen, Y. Li, C. H. Lin et al., “Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma,” Nature Medicine, vol. 19, no. 2, pp. 209–216, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Lu, T. Shan, S. He et al., “Overexpression of CENP-H as a novel prognostic biomarker for human hepatocellular carcinoma progression and patient survival,” Oncology Reports, vol. 30, no. 5, pp. 2238–2244, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Holmgren and J. Lu, “Thioredoxin and thioredoxin reductase: current research with special reference to human disease,” Biochemical and Biophysical Research Communications, vol. 396, no. 1, pp. 120–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Trachootham, J. Alexandre, and P. Huang, “Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?” Nature Reviews Drug Discovery, vol. 8, no. 7, pp. 579–591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M.-H. Yoo, X.-M. Xu, B. A. Carlson, V. N. Gladyshev, and D. L. Hatfield, “Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells,” Journal of Biological Chemistry, vol. 281, no. 19, pp. 13005–13008, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. M.-H. Yoo, X.-M. Xu, B. A. Carlson, A. D. Patterson, V. N. Gladyshev, and D. L. Hatfield, “Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication,” PLoS ONE, vol. 2, no. 10, Article ID e1112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. R. L. Poerschke and P. J. Moos, “Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunction,” Biochemical Pharmacology, vol. 81, no. 2, pp. 211–221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Tobe, M.-H. Yoo, N. Fradejas et al., “Thioredoxin reductase 1 deficiency enhances selenite toxicity in cancer cells via a thioredoxin-independent mechanism,” Biochemical Journal, vol. 445, no. 3, pp. 423–430, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. D. K. Smart, K. L. Ortiz, D. Mattson et al., “Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress,” Cancer Research, vol. 64, no. 18, pp. 6716–6724, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. M. T. Kuo and N. Savaraj, “Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers,” Molecular Carcinogenesis, vol. 45, no. 9, pp. 701–709, 2006. View at Publisher · View at Google Scholar · View at Scopus